Estabilización de la prostaglandina e1 (Pge1) para el tratamiento coadyuvante de la claudicación intermitente

Introduction: In the treatment of intermittent claudication some pharmacologic measures can be used and among them is prostaglandin which produces a vasodilatory effect in patients. The pharmacologic presentation´s way implies a big challenge to keep the molecule stable in the final product, since there are small impurities that can lead to undesired effects. Objective: Analyze the stability of prostaglandina E1 for the adjuvant treatment of intermittent claudication in ampoules with onepointcut system and rubber stoppers. Methods: It was made a review of the literature on clinical studies in which it was used the drug Alprostadil (pharmaceutical name of prostagladina E1) and that backed up its response´s capacity. Then, it was reviewed the pharmacotechnics and the pharmacodynamics of its action mechanisms and the relation between the concentration and the effect of it in the organism. Finally, the articles on conservation, transportation and management as thermolabile drug of frequent use in the hospital field were reviewed. Conclusions: Prostaglandin E1 has proved to be an alternative and a complement to the non-invasive treatment of intermittent claudication. The specific treatment with Alprostadil in ampoules with onepointcut system offers according to the established protocol security to the patients and produces a notable improvement in the quality of life in occlusive arterial disease; in contrast to the use of rubber stoppers, due to the risks of contamination by the interaction among its components with the active molecule of the drug.